Skip to content
HowShorted

OCULAR THERAPEUTIX, INC short interest in 2019

In 2019, OCULAR THERAPEUTIX, INC's disclosed short interest ran from 13.65% of shares outstanding on 15 Jan 2019 to 13.52% on 31 Dec 2019, a change of -0.13 percentage points. The year's high was 21.61% on 28 Jun 2019 and its low 12.68% on 30 Sep 2019, averaging 16.39% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 24.90 days on 15 May 2019. Full history: OCULAR THERAPEUTIX, INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for OCULAR THERAPEUTIX, INC in 2019

2019 in figures

Start of year
13.65% (15 Jan 2019)
End of year
13.52% (31 Dec 2019)
Change
-0.13 pp
High
21.61% (28 Jun 2019)
Low
12.68% (30 Sep 2019)
Average
16.39%
Highest days to cover
24.90 (15 May 2019)
SEC filings marked
8

Every report in 2019

OCULAR THERAPEUTIX, INC short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 201913.65%11.51
31 Jan 201913.80%17.05
15 Feb 201914.63%19.67
28 Feb 201916.51%7.49
15 Mar 201917.33%13.6010-K filed, results (8-K)
29 Mar 201917.18%14.74
15 Apr 201918.61%16.15
30 Apr 201919.60%14.72
15 May 201920.85%24.9010-Q filed, results (8-K)
31 May 201921.52%7.86
14 Jun 201920.92%9.24
28 Jun 201921.61%7.96
15 Jul 201919.23%6.58
31 Jul 201918.85%10.74
15 Aug 201915.69%14.1610-Q filed, results (8-K)
30 Aug 201914.28%12.18
13 Sep 201913.54%19.05
30 Sep 201912.68%11.78
15 Oct 201913.79%10.38
31 Oct 201914.07%22.75
15 Nov 201913.44%12.9510-Q filed, results (8-K)
29 Nov 201914.31%12.43
13 Dec 201913.65%9.63
31 Dec 201913.52%9.82

See also: OCULAR THERAPEUTIX, INC's full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.